Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
43 Cards in this Set
- Front
- Back
|
proteins the body produces involved in the immune response
|
antibodies and immunoglobulins
|
|
|
5 antibody isotopes
|
IgG, IgA, IgM, IgD, IgE
|
|
|
antibody release initially
|
IgM
|
|
|
most abundant antibody
|
IgG
|
|
|
antibody in secretions
|
IgA
|
|
|
types of vaccine antigens
|
live attenuated
inactivated |
|
|
type of antigen that produces the most effective immune response
|
live antigen
|
|
|
type of antigen that produces longer protection
|
live antigen
|
|
|
are live antigen vaccines able to replicate in the body
|
YES
|
|
|
vaccines that are made up of toxoids, subunit, and/or subvirion products
|
protein based inactivated
|
|
|
vaccines made of pure cell wall material
|
polysaccharide based inactivated
|
|
|
what type of immunity do inactivated vaccines produce
|
active immunity
|
|
|
immunity produced by one's own body
|
active
|
|
|
active immunity is temporary or permanent?
|
permanent
|
|
|
immunity transferred from one organism or another
|
passive
|
|
|
passive immunity is temporary or permanent?
|
Temporary
|
|
|
effective vaccination programs include
|
1. education for healthcare providers
2. publicity/patient education 3. ID high risk groups 4. remove barriers |
|
|
when a patient is eligible for, but does not recieve a vaccination
|
missed oppurtunity
|
|
|
two chief barriers to vaccination
|
time
space |
|
|
T/F two or more vaccines can be given together
|
T need seperate inj. sites
|
|
|
how long should live vaccines be seperated if not given at the same time
|
4 weeks
|
|
|
does increasing the time interval between doses of multi-dose vaccines reduce effectiveness
|
NO, but reducing the time between doses may decrease effectiveness
|
|
|
which vaccine requires restarting the series if a dose is not given on time
|
oral typhoid
|
|
|
influenza virus
|
single stranded, helically shaped, RNA
|
|
|
people at risk for influenza
|
elderly
very young those with chronic dz |
|
|
peak influenza times
|
late december thru March
|
|
|
influenza A affects
|
humans and other animals
|
|
|
influenza B affects
|
only humans
mostly younger children (milder dz) |
|
|
influenza C affects
|
most cases are subclinical in humans
|
|
|
influenza transmission
|
aerosolized/ droplet
|
|
|
influenza sxs
|
abrupt fever
myalgia sore thrat cough HA |
|
|
medication associated with Reye's syndrome in children
|
aspirin
|
|
|
complications of flu
|
pneumonia
myocarditis worsening bronchitis |
|
|
types of flu vaccine
|
LAIV and TIV
|
|
|
composition of flu vaccine
|
two influenza A and one influenza B
|
|
|
what are influenza vaccines produced in
|
eggs
|
|
|
administration of TIV
|
IM in deltoid
|
|
|
administration of LAIV
|
IN
|
|
|
LAIV approved for use in:
|
healthy persons 5-49 yo
|
|
|
common ADR for TIV
|
local inj. site reactions
|
|
|
common ADR for LAIV
|
cold symptoms
|
|
|
CI to influenza vaccine
|
previous allergic rxn
egg allergy mod/severe illness |
|
|
CI to LAIV specifically
|
children <5
adults >50 those taking aspirin chronically immunocompromised asthma hx pregnant chronic dz hx |
